Clinical Trials Logo
  1. Home
  2. Cytokine Release Syndrome
  3. NCT04071366

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Cytokine Release Syndrome Clinical Trial

Official title:
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Clinical Trial Summary

"The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematologic malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04071366
Study type Interventional
Source Incyte Corporation
Contact
Status Completed
Phase Phase 2
Start date February 7, 2020
Completion date August 22, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Terminated NCT04540120 - Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04975555 - Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Phase 2
Terminated NCT04403685 - Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Phase 3
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT05349669 - Jafron Haemoadsorption During Cardiopulmonary Bypass Phase 2
Completed NCT04720378 - Safety and Tolerability Study of IV ST266 in COVID-19 Subjects Phase 1
Terminated NCT04415073 - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 Phase 2
Completed NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Phase 1/Phase 2
Completed NCT04403061 - Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Completed NCT04475588 - Efficacy and Safety of Itolizumab in COVID-19 Complications Phase 2
Terminated NCT04377503 - Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Phase 2
Recruiting NCT04781803 - Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome Phase 2
Completed NCT01353157 - Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Recruiting NCT04048434 - Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) N/A